Literature DB >> 33435249

The Bayesian Design of Adaptive Clinical Trials.

Alessandra Giovagnoli1.   

Abstract

This paper presents a brief overview of the recent literature on adaptive design of clinical trials from a Bayesian perspective for statistically not so sophisticated readers. Adaptive designs are attracting a keen interest in several disciplines, from a theoretical viewpoint and also-potentially-from a practical one, and Bayesian adaptive designs, in particular, have raised high expectations in clinical trials. The main conceptual tools are highlighted here, with a mention of several trial designs proposed in the literature that use these methods, including some of the registered Bayesian adaptive trials to this date. This review aims at complementing the existing ones on this topic, pointing at further interesting reading material.

Entities:  

Keywords:  Bayesian designs; adaptive designs; adaptive randomization; clinical trials; predictive power; target allocation

Mesh:

Year:  2021        PMID: 33435249      PMCID: PMC7826635          DOI: 10.3390/ijerph18020530

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  71 in total

1.  Bayesian optimal designs for Phase I clinical trials.

Authors:  Linda M Haines; Inna Perevozskaya; William F Rosenberger
Journal:  Biometrics       Date:  2003-09       Impact factor: 2.571

2.  Are outcome-adaptive allocation trials ethical?

Authors:  Spencer Phillips Hey; Jonathan Kimmelman
Journal:  Clin Trials       Date:  2015-02-03       Impact factor: 2.486

3.  Continual Reassessment and Related Dose-Finding Designs.

Authors:  John O'Quigley; Mark Conaway
Journal:  Stat Sci       Date:  2010       Impact factor: 2.901

4.  Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Authors:  Hope S Rugo; Olufunmilayo I Olopade; Angela DeMichele; Christina Yau; Laura J van 't Veer; Meredith B Buxton; Michael Hogarth; Nola M Hylton; Melissa Paoloni; Jane Perlmutter; W Fraser Symmans; Douglas Yee; A Jo Chien; Anne M Wallace; Henry G Kaplan; Judy C Boughey; Tufia C Haddad; Kathy S Albain; Minetta C Liu; Claudine Isaacs; Qamar J Khan; Julie E Lang; Rebecca K Viscusi; Lajos Pusztai; Stacy L Moulder; Stephen Y Chui; Kathleen A Kemmer; Anthony D Elias; Kirsten K Edmiston; David M Euhus; Barbara B Haley; Rita Nanda; Donald W Northfelt; Debasish Tripathy; William C Wood; Cheryl Ewing; Richard Schwab; Julia Lyandres; Sarah E Davis; Gillian L Hirst; Ashish Sanil; Donald A Berry; Laura J Esserman
Journal:  N Engl J Med       Date:  2016-07-07       Impact factor: 91.245

5.  A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials.

Authors:  P F Thall; R Simon
Journal:  Control Clin Trials       Date:  1994-12

6.  Phase II trial design with Bayesian adaptive randomization and predictive probability.

Authors:  Guosheng Yin; Nan Chen; J Jack Lee
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2012-03-01       Impact factor: 1.864

7.  Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial.

Authors:  Karen C Johnston; Askiel Bruno; Qi Pauls; Christiana E Hall; Kevin M Barrett; William Barsan; Amy Fansler; Katrina Van de Bruinhorst; Scott Janis; Valerie L Durkalski-Mauldin
Journal:  JAMA       Date:  2019-07-23       Impact factor: 56.272

8.  A two-stage Bayesian design with sample size reestimation and subgroup analysis for phase II binary response trials.

Authors:  Wei Zhong; Joseph S Koopmeiners; Bradley P Carlin
Journal:  Contemp Clin Trials       Date:  2013-04-11       Impact factor: 2.226

9.  Adaptive decision making in a lymphocyte infusion trial.

Authors:  Peter F Thall; Lurdes Y T Inoue; Thomas G Martin
Journal:  Biometrics       Date:  2002-09       Impact factor: 2.571

Review 10.  Bayesian clinical trials.

Authors:  Donald A Berry
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

View more
  5 in total

1.  Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer.

Authors:  Bethany Jablonski Horton; Nolan A Wages; Ryan D Gentzler
Journal:  Int J Environ Res Public Health       Date:  2021-10-30       Impact factor: 3.390

2.  Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.

Authors:  Elja Arjas; Dario Gasbarra
Journal:  BMC Med Res Methodol       Date:  2022-02-20       Impact factor: 4.615

3.  Informed Bayesian survival analysis.

Authors:  František Bartoš; Frederik Aust; Julia M Haaf
Journal:  BMC Med Res Methodol       Date:  2022-09-10       Impact factor: 4.612

4.  Left atrial appendage occlusion should be offered only to select atrial fibrillation patients.

Authors:  Muhammad Bilal Munir; Jonathan C Hsu
Journal:  Heart Rhythm O2       Date:  2022-08-22

Review 5.  Adaptive magnetic resonance image guided radiation for intact localized prostate cancer how to optimally test a rapidly emerging technology.

Authors:  William A Hall; Amar U Kishan; Emma Hall; Himanshu Nagar; Danny Vesprini; Eric Paulson; Uulke A Van der Heide; Colleen A F Lawton; Linda G W Kerkmeijer; Alison C Tree
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.